Skip to Content
Non-Coding RNANon-Coding RNA
  • Review
  • Open Access

1 February 2021

9 Pages

MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease

,
,
and
1
Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Lifespan Academic Medical Center, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA
2
Department of Pathology and Laboratory Medicine, Boston University School of Medicine, 670 Albany Street, Boston, MA 02118, USA
3
German Center for Neurodegenerative Diseases, Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, 37075 Göttingen, Germany
*
Author to whom correspondence should be addressed.

Abstract

The neurological damage of Alzheimer’s disease (AD) is thought to be irreversible upon onset of dementia-like symptoms, as it takes years to decades for occult pathologic changes to become symptomatic. It is thus necessary to identify individuals at risk for the development of the disease before symptoms manifest in order to provide early intervention. Surrogate markers are critical for early disease detection, stratification of patients in clinical trials, prediction of disease progression, evaluation of response to treatment, and also insight into pathomechanisms. Here, we review the evidence for a number of microRNAs that may serve as biomarkers with possible mechanistic insights into the AD pathophysiologic processes, years before the clinical manifestation of the disease.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.